Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor

Novel potent and selective p53-HDM2 inhibitor

Novel potent Jak2 type 1 inhibitor

Novel dual inhibitor of TORC1 and TORC2

Novel BCR-ABL Kinase Inhibitor

Novel potent and selective antagonist of somatostatin receptor subtype SST(3)

Novel Inhibitor of the Cysteine Protease Cathepsin K

Novel phosphodiesterase 4D (PDE4D) inhibitor

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Potent and selective p53-MDM2 binding inhibitor

p53-MDM2 binding inhibitor; p-Glycoprotein (p-gp) transport substrate; Antitumer agent

Novel modulator of the NusB-NusE interaction

Novel Inhibitor of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity

Novel Potent Cell-Active Inhibitor of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition

Novel inhibitor of Helicobacter pylori , targeting H. pylori's respiratory complex I subunit NuoD

Nucleosidic antibiotic

First-in-class activin antagonist, specifically binding to ALK4, which opens a completely new approach to inhibiting the activity of TGF-beta receptor superfamily members

Novel potent activin antagonist

Novel highly potent and selective MEK4 inhibitor

Novel DNA methytransferase inhibitor, be significantly safer and more effective than decitabine in xenograft models of human leukemia and colon cancer

Novel potent CDK2 inhibitor

Novel potent and selective non-thiazolidinedione partial Peroxisome_proliferator-activated_receptor>PPARγ agonist, acting as an antibiotic effectively against bacterial persisters

Novel potent STAT3 inhibitor

Novel potent STAT3 inhibitor, exhibiting much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines

The first NTR-responsive PROTAC, incorporating the caging group on the Von Hippel-Lindau (VHL) E3 ubiquitin ligase ligand, efficiently degrading the EGFR protein and subsequently exert antitumor efficacy